No, gliclazide should NOT be discontinued - instead, reduce the dose to minimize hypoglycemia risk while maintaining glycemic efficacy
With an A1C of 10%, this patient requires intensification, not de-escalation of therapy. However, the gliclazide dose should be reduced (not stopped) to prevent hypoglycemia when combined with the highly effective tirzepatide regimen already in place.
Rationale for Dose Reduction (Not Discontinuation)
The FDA label for dapagliflozin explicitly warns that SGLT2 inhibitors increase hypoglycemia risk when combined with insulin secretagogues like sulfonylureas, and recommends "a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia" 1. This is a dose adjustment recommendation, not a discontinuation mandate.
Recent real-world evidence from 2026 demonstrates that in older patients on tirzepatide, physicians who proactively reduced doses of sulfonylureas (rather than stopping them entirely) achieved excellent glycemic control - 66.9% reached A1C <7.0% without severe hypoglycemia 2. This supports maintaining gliclazide at a reduced dose.
Why Not Stop Gliclazide Completely?
A 2026 multicenter randomized trial showed that the fixed-dose combination of dapagliflozin + gliclazide 60mg SR was significantly more effective than dapagliflozin monotherapy in reducing A1C (mean reduction to 6.97% vs 7.32%, p<0.001) with a favorable safety profile 3. This demonstrates additive benefit when these agents are used together.
Additionally, a 2019 Japanese study found that when adding SGLT2 inhibitors, maintaining sulfonylurea at the lowest dose resulted in 91.4% of patients achieving non-exacerbation of A1C, compared to only 75.9% when sulfonylurea was discontinued (p=0.024) 4.
The High A1C Context
Current ADA/EASD guidelines state that when A1C is ≥1.5% above goal (which applies here with A1C of 10%), patients require dual-combination therapy or more potent agents 5. While tirzepatide is highly potent, this patient's A1C of 10% indicates severe hyperglycemia requiring all available therapeutic mechanisms, not medication reduction.
Practical Algorithm
Immediate action:
- Reduce gliclazide to the lowest available dose (typically 30-40mg daily if using modified release formulations)
- Continue metformin, dapagliflozin, and tirzepatide unchanged
- Monitor for hypoglycemia symptoms closely for 2-4 weeks
At 3-month follow-up:
- If A1C reaches <7% and patient experiences hypoglycemia: Consider discontinuing gliclazide at that point
- If A1C remains >8%: Maintain current regimen and consider uptitrating tirzepatide dose if not at maximum
- If A1C 7-8%: Continue current regimen including reduced-dose gliclazide
Critical Caveats
The 2024 ADA guidelines emphasize that GLP-1 RAs (and by extension, tirzepatide) have lower hypoglycemia risk and favorable cardiovascular/kidney endpoints compared to sulfonylureas 5. However, this doesn't mandate immediate sulfonylurea discontinuation in poorly controlled diabetes - it informs long-term strategy once glycemic control is achieved.
A 2026 review on medication de-escalation confirms that sulfonylureas should be among the first agents discontinued, but this applies to patients who have already achieved glycemic targets 6. Your patient is far from target.
The key principle: Reduce the hypoglycemia-inducing agent's dose preemptively when intensifying with tirzepatide, but don't sacrifice glycemic efficacy by complete discontinuation when A1C is critically elevated at 10%.